Jpmorgan Chase & CO Verve Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,647,844 shares of VERV stock, worth $7.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,647,844

Previous 1,691,352 2.57%

Holding current value

$7.58 Million

Previous $8.25 Million 3.37%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$4.4 - $7.86 $191,435 - $341,972	-43,508 Reduced 2.57%	1,647,844 $7.98 Million
Q2 2024 Aug 12, 2024	BUY	$4.76 - $12.79 $943,917 - $2.54 Million	198,302 Added 13.28%	1,691,352 $8.25 Million
Q1 2024 May 10, 2024	SELL	$10.81 - $17.96 $6.11 Million - $10.2 Million	-565,349 Reduced 27.47%	1,493,050 $19.8 Million
Q4 2023 Feb 12, 2024	SELL	$8.84 - $18.7 $3.96 Million - $8.37 Million	-447,497 Reduced 17.86%	2,058,399 $28.7 Million
Q3 2023 Nov 14, 2023	BUY	$11.42 - $20.82 $7.62 Million - $13.9 Million	666,910 Added 36.27%	2,505,896 $33.2 Million
Q2 2023 Aug 11, 2023	SELL	$13.34 - $19.9 $925,502 - $1.38 Million	-69,378 Reduced 3.64%	1,838,986 $34.5 Million
Q1 2023 May 18, 2023	BUY	$14.3 - $24.01 $805,619 - $1.35 Million	56,337 Added 3.04%	1,908,364 $27.5 Million
Q1 2023 May 11, 2023	BUY	$14.3 - $24.01 $908,979 - $1.53 Million	63,565 Added 3.55%	1,852,027 $26.7 Million
Q4 2022 Feb 13, 2023	SELL	$17.85 - $40.7 $2.32 Million - $5.29 Million	-130,028 Reduced 6.78%	1,788,462 $34.6 Million
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $8.81 Million - $23.4 Million	563,852 Added 41.62%	1,918,490 $65.9 Million
Q2 2022 Aug 11, 2022	BUY	$11.14 - $23.17 $2.63 Million - $5.46 Million	235,804 Added 21.08%	1,354,638 $20.7 Million
Q1 2022 May 11, 2022	BUY	$20.92 - $39.36 $5.05 Million - $9.51 Million	241,536 Added 27.53%	1,118,834 $25.5 Million
Q4 2021 Feb 10, 2022	SELL	$31.94 - $54.82 $720,789 - $1.24 Million	-22,567 Reduced 2.51%	877,298 $32.3 Million
Q3 2021 Nov 12, 2021	BUY	$46.0 - $73.99 $41.4 Million - $66.6 Million	899,865 New	899,865 $42.3 Million

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $276M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Verve Therapeutics, Inc. Transaction History